Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

NCT02129647 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Neurofibromatosis Type 2
Vestibular Schwannomas

Interventions

DRUG: Axitinib

Sponsor

NYU Langone Health